News & Updates

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor

05/14/2021

Excerpt from the Press Release: SAN MATEO, Calif., May 4, 2021 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next…

Read More

Key Changes In The Revised EMA Guidance On Clinical Trials During COVID

05/13/2021

Excerpt from the Article: In February, the European Medicines Agency (EMA) released the fourth version of its Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic. As the pandemic continues to impact clinical research worldwide, these updated guidelines reflect the EMA’s evolving stance, clarifying questions raised by previous versions and taking into account…

Read More

Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model

05/13/2021

Excerpt from the Press Release: WAYNE, Pa., May 4, 2021 /PRNewswire/ — In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at Moffitt Cancer Center, Sarin Lab at the Stanford University School of Medicine and NFlection Therapeutics demonstrate positive efficacy in preclinical models for the…

Read More

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

05/13/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2…

Read More

RSIP Vision Launches an Advanced AI-Based Tool for Prostate MRI and Ultrasound Registration Enabling Precise Navigation in Key Procedures

05/13/2021

Excerpt from the Press Release: TEL AVIV, Israel & SAN JOSE, Calif.–(BUSINESS WIRE)–RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool. The tool’s fully automated, deep learning-based capabilities provide a robust method that utilizes a registered MRI scan…

Read More

Protein ‘signature’ linked to severe COVID-19 outcomes identified, Mass General Hospital study says

05/12/2021

Excerpt from the Article: Massachusetts General Hospital researchers have identified what’s known as a protein “signature” linked to severe health outcomes including death for people who contract COVID-19, according to an article published Tuesday in the Harvard Gazette. Researchers led by Dr. Marcia Goldberg, an MGH infectious disease expert, and Dr. Michael Filbin, an attending physician…

Read More

Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

05/12/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of data that further validate the potential of its mass cytometry technologies, CyTOF® and Imaging Mass Cytometry™ (IMC™), to provide new approaches to…

Read More

Researchers identify protein “signature” of severe COVID-19

05/11/2021

Excerpt from the Press Release: Researchers at Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in…

Read More

Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

05/11/2021

Excerpt from the Press Release: HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion’s lead candidate, [225Ac]-FPI-1434…

Read More

Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

05/10/2021

Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that the first patient has been treated in the company’s Phase 2/3 pivotal trial evaluating ADG20 for the prevention of COVID-19, known as the EVADE trial. Trial initiation is supported bypositive preliminary…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives